J&J Propulsid
Executive Summary
Investigational limited access program for Janssen's cisapride will begin May 1 for three treatment protocols of patients who have failed all other standard therapies, an April 12 "Dear Doctor" letter states. The protocols include: adults with gastroesophageal reflux disease, gastroparesis, pseudo-obstruction and severe chronic constipation; pediatrics with pseudo-obstruction or refractory GERD associated with failure to thrive, asthma, bradycardia, apnea or other serious conditions; and neonates with feeding intolerance. The protocols require electrocardiograms every three months for adults and every two months for outpatient pediatric patients. Public Citizen's Health Research Group has asked for a complete withdrawal of the drug, reporting that 103 deaths were associated with Propulsid between Dec. 31 and March 28. J&J announced March 23 it will limit access to the drug due to cardiac events (1"The Pink Sheet" March 27, p. 3)
You may also be interested in...
J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use
Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).
J&J Propulsid Compassionate IND Program Expands To Allow Emergency Use
Janssen is adding three IND treatment protocols to its limited access program for Propulsid (cisapride).
Propulsid Limited Access Program Allows Off-Label Use To Continue
FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.